Join the 'Eptifibatide' group to help and get support from people like you.
Posted 9 Dec 2009 by Drugs.com
TUESDAY, Dec. 8 – More than one-fifth of patients on dialysis who undergo angioplasty are given blood thinners they should not be given, new research shows. As a result, these patients are subject to a higher rate of bleeding during their hospital stay and may even be at a higher risk of dying, according to a report in the Dec. 9 issue of the Journal of the American Medical Association. The drugs in question are enoxaparin (Lovenox), a low-molecular-weight heparin, and eptifibatide (Integrilin). The U.S. Food and Drug Administration (FDA) has determined that neither medication should be used in people undergoing dialysis. "The study does validate the FDA's directed labeling [of these drugs] as contraindicated, and it supports avoiding use of these drugs in dialysis patients," said study author Dr. Thomas Tsai, director of interventional cardiology at the Denver VA Medical Center and an ... Read more